Synlogic Inc Asset Resilience Ratio
Synlogic Inc asset resilience ratio. Synlogic Inc (SYBX) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Synlogic Inc (SYBX) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Synlogic Inc (2015–2024)
Asset resilience ratio of Synlogic Inc from 2015 to 2024. This chart shows how Synlogic Inc's Asset Resilience Ratio has changed over time. Read Synlogic Inc debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Synlogic Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Synlogic Inc (SYBX) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Synlogic Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Synlogic Inc Industry Peers by Asset Resilience Ratio
Compare Synlogic Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Synlogic Inc Asset Resilience Ratio by Year (2015–2024)
Synlogic Inc asset resilience ratio by year from 2015 to 2024. The table below shows the annual Asset Resilience Ratio data for Synlogic Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | $0.00 | $19.83 Million | -- |
| 2023-12-31 | 31.48% | $23.79 Million | $75.55 Million | -24.23pp |
| 2022-12-31 | 55.71% | $61.77 Million | $110.86 Million | -8.47pp |
| 2021-12-31 | 64.18% | $112.15 Million | $174.74 Million | +16.95pp |
| 2020-12-31 | 47.23% | $67.94 Million | $143.84 Million | -2.29pp |
| 2019-12-31 | 49.52% | $93.39 Million | $188.57 Million | -29.91pp |
| 2018-12-31 | 79.43% | $111.48 Million | $140.34 Million | +50.76pp |
| 2017-12-31 | 28.67% | $28.59 Million | $99.70 Million | -40.00pp |
| 2016-12-31 | 68.67% | $44.07 Million | $64.17 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $90.92 Million | -- |
About Synlogic Inc
Synlogic, Inc. does not have significant operations. It was previously engaged in the discovery and development of synthetic biotics to treat metabolic diseases. Synlogic, Inc. is based in Winchester, Massachusetts.